Resources

1 Resources for

elestat

Inspire Pharmaceuticals, Inc. F4Q and Full Year 2008 Earnings Call Transcript: Question-and-Answer SessionOperator Operator Instructions Your first question comes from Liana Moussatos of Wedbush Morgan. Liana Moussatos - Wedbush Morgan Could you repeat the quarter-over-quarter AzaSite sales and prescription growth and then what was the stock based compensation amount? Also, how many potential partners are in discussion...; Tags: Commercialization, Stock, Call Transcript, Earnings, Inspire Pharmaceuticals Inc., Elestat, Investment, Benefits, Finance, Human Resources, Seeking Alpha; Earnings calls 2009-03-03

Inspire Reports Third Quarter 2006 Financial Results: Third Quarter 2006 Revenue Increases 48% from Third Quarter 2005 DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today reported financial results for the third quarter ended September 30, 2006. Total revenue for the third quarter of 2006 was $9.7 million, which was generated from co-promotion activities, compared...; Tags: Allergan Inc., Company, FINANCE, Inspire Pharmaceuticals Inc., marketing, R&D, revenue, SALES, SEC, U.S.; Research articles 2006-11-07
Inspire Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript: Question-and-Answer SessionOperator Thank you, sir. Operator instructions Your first question comes from the line of Liana Moussatos with Wedbush. Liana Moussatos – Wedbush Morgan What was the non-cash stock option expense in Q1? Tom Staab Liana, I don’t have that number on my – at my fingertips, but typical...; Tags: Restructuring, Call Transcript, Quarter, Earnings, Inspire Pharmaceuticals Inc., Research & Development, Business Operations, Seeking Alpha; Earnings calls 2009-05-08